164 related articles for article (PubMed ID: 37147682)
1. The long-term effect of generic price competition on the Hungarian statin market.
Répásy B; Gazsó T; Elmer D; Pónusz-Kovács D; Kajos FL; Csákvári T; Kovács B; Boncz I
BMC Health Serv Res; 2023 May; 23(1):447. PubMed ID: 37147682
[TBL] [Abstract][Full Text] [Related]
2. [The effect of generic price competition on drug consumption and health insurance pharmaceutical expenditures in Hungary].
Répásy B; Endrei D; Zemplényi A; Agoston I; Hornyák L; Nagy Z; Csákvári T; Vajda R; Boncz Imre
Acta Pharm Hung; 2015; 85(3):83-8. PubMed ID: 26642646
[TBL] [Abstract][Full Text] [Related]
3. Price competition and reimbursement of biosimilar granulocyte-colony stimulating factor in Hungary.
Hornyák L; Nagy Z; Ilku L; Tálos Z; Endrei D; Ágoston I; Csákvári T; Danku N; Répásy B; Boncz I
Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):725-731. PubMed ID: 30763134
[No Abstract] [Full Text] [Related]
4. [Assessment of annual health insurance reimbursement for oncology drugs in Hungary].
Boncz I; Donkáné Verebes E; Oberfrank F; Kásler M
Magy Onkol; 2010 Dec; 54(4):283-8. PubMed ID: 21163758
[TBL] [Abstract][Full Text] [Related]
5. [The patients' cost of the montelukast therapy due to the generic substitution].
Répásy B; Endrei D; Zemplényi A; Ágoston I; Boncz I
Orv Hetil; 2018 Apr; 159(17):682-687. PubMed ID: 29681174
[TBL] [Abstract][Full Text] [Related]
6. Trends in Use and Expenditures for Brand-name Statins After Introduction of Generic Statins in the US, 2002-2018.
Lin SY; Baumann K; Zhou C; Zhou W; Cuellar AE; Xue H
JAMA Netw Open; 2021 Nov; 4(11):e2135371. PubMed ID: 34807258
[TBL] [Abstract][Full Text] [Related]
7. [Health insurance pharmaceutical expenditures in Hungary].
Eisingerné Balassa B; Csákvári T; Ágoston I
Orv Hetil; 2019 Feb; 160(Suppl 1):49-54. PubMed ID: 30724598
[TBL] [Abstract][Full Text] [Related]
8. Expiry of patent protection on statins: effects on pharmaceutical expenditure in Australia.
Clarke PM; Fitzgerald EM
Med J Aust; 2010 Jun; 192(11):633-6. PubMed ID: 20528715
[TBL] [Abstract][Full Text] [Related]
9. Effective policy initiatives to constrain lipid-lowering drug expenditure growth in South Korea.
Bae G; Park C; Lee H; Han E; Kim DS; Jang S
BMC Health Serv Res; 2014 Mar; 14():100. PubMed ID: 24589172
[TBL] [Abstract][Full Text] [Related]
10. [Bisphosphonate use and related pharmaceutical issues II].
Veszelyné Kotan E; Mészáros Á
Acta Pharm Hung; 2016; 86(1):23-34. PubMed ID: 27295874
[TBL] [Abstract][Full Text] [Related]
11. [Health economics of oncology care: financial effect of performance volume limit (PVL)].
Boncz I; Donkáné Verebes E; Oberfrank F; Kásler M
Magy Onkol; 2010 Mar; 54(1):35-9. PubMed ID: 20350866
[TBL] [Abstract][Full Text] [Related]
12. [Priorisation in health-care; drug-reimbursement priorities in Hungary in 2004].
Kárpati K; Brandtmüller A; Májer I; Gulácsi L
Acta Pharm Hung; 2006; 76(4):191-9. PubMed ID: 17575799
[TBL] [Abstract][Full Text] [Related]
13. Effect of Generic Competition on Atorvastatin Prescribing and Patients' Out-of-Pocket Spending.
Luo J; Seeger JD; Donneyong M; Gagne JJ; Avorn J; Kesselheim AS
JAMA Intern Med; 2016 Sep; 176(9):1317-23. PubMed ID: 27367749
[TBL] [Abstract][Full Text] [Related]
14. [Utilization indicators of balneotherapy in Hungary].
Varga V; Boncz I; Sebestyén A; Endrei D; Ágoston I; Péter I; Molics B
Orv Hetil; 2019 Feb; 160(Suppl 1):22-28. PubMed ID: 30724601
[TBL] [Abstract][Full Text] [Related]
15. Does therapeutic reference pricing always result in cost-containment? The Hungarian evidence.
Kaló Z; Muszbek N; Bodrogi J; Bidló J
Health Policy; 2007 Mar; 80(3):402-12. PubMed ID: 16730848
[TBL] [Abstract][Full Text] [Related]
16. [Epidemiological disease burden and annual health insurance treatment cost of colorectal cancer in Hungary].
Kívés Z; Endrei D; Elmer D; Csákvári T; Kajos LF; Boncz I; Mangel L; Mihály-Vajda R
Orv Hetil; 2021 Mar; 162(162 Suppl 1):14-21. PubMed ID: 33774604
[TBL] [Abstract][Full Text] [Related]
17. National Trends in Statin Use and Expenditures in the US Adult Population From 2002 to 2013: Insights From the Medical Expenditure Panel Survey.
Salami JA; Warraich H; Valero-Elizondo J; Spatz ES; Desai NR; Rana JS; Virani SS; Blankstein R; Khera A; Blaha MJ; Blumenthal RS; Lloyd-Jones D; Nasir K
JAMA Cardiol; 2017 Jan; 2(1):56-65. PubMed ID: 27842171
[TBL] [Abstract][Full Text] [Related]
18. Exploring the Evolution of Statin Pricing in Australia: Observations of Price Disclosure Effects on Pharmaceutical Benefits Scheme Expenditure.
Lee L; Kim H
Value Health Reg Issues; 2024 Mar; 40():27-34. PubMed ID: 37972431
[TBL] [Abstract][Full Text] [Related]
19. Evolutions in both co-payment and generic market share for common medication in the Belgian reference pricing system.
Fraeyman J; Verbelen M; Hens N; Van Hal G; De Loof H; Beutels P
Appl Health Econ Health Policy; 2013 Oct; 11(5):543-52. PubMed ID: 24062144
[TBL] [Abstract][Full Text] [Related]
20. The impact of changes in national prescribing conditions for statins on their public expenditure and utilization in the Czech Republic 1997-2013.
Fuksa L; Vocelka M; Vytrisalova M
Health Policy; 2015 Sep; 119(9):1255-64. PubMed ID: 25929214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
